COVID-19 and vaccination: myths vs science

References

• Chavda VP, Gajjar N, Shah N, et al. Darunavir ethanolate: repurposing an anti-HIV drug in COVID-19 treatment. Eur J Med Chem Reports [Internet]. 2021;3:100013. https://www.sciencedirect.com/science/article/pii/S2772417421000133
   PubMedGoogle Scholar
• Yin Y, Wunderink RG. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130–137.
   PubMed Web of Science ®Google Scholar
• Xu J, Zhao S, Teng T, et al. Systematic comparison of two animal-to-human transmitted human coronaviruses: SARS-CoV-2 and SARS-CoV. Viruses. 2020;12(2): 244.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Hossain MK, Beladiya J, et al., Nucleic Acid Vaccines for COVID-19: a paradigm shift in the vaccine development arena. Biologics. 2021;1(3): 337–356.
   Google Scholar
• Chavda VP, Apostolopoulos VM. An opportunistic infection in the aged immunocompromised individual: a reason for concern in COVID-19. Maturitas [Internet]. 2021;58:58–61. Available from: https://www.sciencedirect.com/science/article/pii/S0378512221001365
   Google Scholar
• Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271–280.e8.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vora LK, Vihol DR. COVAX-19Ⓡ Vaccine: completely blocks virus transmission to non-immune individuals. Clin Complement Med Pharmacol [Internet]. 2021;1(1):100004. Available from: https://www.sciencedirect.com/science/article/pii/S2772371221000048
   Google Scholar
• Chavda VP, Pandya R, Apostolopoulos V. DNA vaccines for SARS-CoV-2: towards third generation vaccination era. Expert Rev Vaccines. 2021;20(12):1549–1560.
   PubMed Web of Science ®Google Scholar
• Gadanec LK, McSweeney KR, Qaradakhi T, et al. Can SARS-CoV-2 virus use multiple receptors to enter host cells? Int J Mol Sci. 2021;23(1):22.
   PubMedGoogle Scholar
• Moore GJ, Pires JM, Kelaidonis K, et al. Receptor interactions of angiotensin ii and angiotensin receptor blockers—relevance to covid-19. Biomolecules. 2021;11(7):1–13.
   Web of Science ®Google Scholar
• Kate Gadanec L, Qaradakhi T, McSweeney K R, et al. Dual targeting of Toll-like receptor 4 and angiotensin-converting enzyme 2: a proposed approach to SARS-CoV-2 treatment. Future Microbiol. 2021;16(4):205–209.
   PubMed Web of Science ®Google Scholar
• Ridgway H, Moore GJ, Mavromoustakos T, et al. Discovery of a new generation of angiotensin receptor blocking drugs: receptor mechanisms and in silico binding to enzymes relevant to SARS-CoV-2. Comput Struct Biotechnol J. 2022;20:2091–2111.
   PubMed Web of Science ®Google Scholar
• Stancioiu F, G PZ, Kteniadakis S, et al. A dissection of SARS‑CoV2 with clinical implications (Review). Int J Mol Med [Internet]. 2020;46(2):489–508
   PubMed Web of Science ®Google Scholar
• Zaim S, Chong JH, Sankaranarayanan V, et al. COVID-19 and multiorgan response. Curr Probl Cardiol [Internet]. 2020 April 28;45(8):100618. Available from: https://pubmed.ncbi.nlm.nih.gov/32439197
   PubMed Web of Science ®Google Scholar
• Magro G. SARS-CoV-2 and COVID-19: is interleukin-6 (IL-6) the ‘culprit lesion’ of ARDS onset? What is there besides Tocilizumab? SGP130Fc. Cytokine X [Internet]. 2020;2(2):100029. https://www.sciencedirect.com/science/article/pii/S2590153220300094
   PubMedGoogle Scholar
• Scavone C, Brusco S, Bertini M, et al., Current pharmacological treatments for COVID-19 : what ’ s next ? Br J Pharmacol. 2020;177(21): 4813–4824.
   PubMed Web of Science ®Google Scholar
• Chung JY, Thone MN, Kwon YJ. COVID-19 vaccines: the status and perspectives in delivery points of view. Adv Drug Deliv Rev. 2021;170:1–25.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Feehan J, Apostolopoulos V. A veterinary vaccine for SARS-CoV-2: the First COVID-19 vaccine for animals. Vaccines (Basel). 2021;9(6):631.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Vora LK, Pandya AK, et al. Intranasal vaccines for SARS-CoV-2: from challenges to potential in COVID-19 management. Drug Discov Today [Internet]. 2021;26(11):2619–2636. Available from: https://www.sciencedirect.com/science/article/pii/S1359644621003317
   PubMed Web of Science ®Google Scholar
• Hossain MK, Hassanzadeganroudsari M, Feehan J, et al. COVID-19 vaccines in the pipeline, are antibodies adequate? Vaccines (Basel). 2021;9(3):241.
   PubMed Web of Science ®Google Scholar
• Hossain MK, Hassanzadeganroudsari M, Feehan J, et al. The race for a COVID-19 vaccine: where are we up to? Expert Rev Vaccines. 2022;21(3):355–376.
   PubMed Web of Science ®Google Scholar
• Mahumud RA, Ali MA, Kundu S, et al. Effectiveness of COVID-19 vaccines against delta variant (B.1.617.2): a meta-analysis. Vaccines (Basel). 2022;10(2):1–12.
   Web of Science ®Google Scholar
• Ridgway H, Chasapis CT, Kelaidonis K, et al. Understanding the driving forces that trigger mutations in SARS-CoV-2: mutational energetics and the role of arginine blockers in COVID-19 therapy. Viruses. 2022;14(5):1029.
   PubMed Web of Science ®Google Scholar
• Hossain MK, Hassanzadeganroudsari M, Apostolopoulos V. The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines? Expert Rev Vaccines. 2021;20(6):635–638.
   PubMed Web of Science ®Google Scholar
• Abdool Karim SS, de Oliveira T. New SARS-CoV-2 variants — clinical, public health, and vaccine implications.N Engl J Med.2021;384(19):1866–1868;[Internet].
   PubMed Web of Science ®Google Scholar
• Chavda VP, Patel AB, Vaghasiya DD. SARS-CoV-2 variants and vulnerability at the global level. J Med Virol [Internet]. 2022;94(7):2986–3005. Available from.
   PubMed Web of Science ®Google Scholar
• Callaway E. Heavily mutated coronavirus variant puts scientists on alert. Nat News. 2021;600(7887):21.
   Google Scholar
• Shang Y, Li H, Zhang R. Effects of pandemic outbreak on economies: evidence from business history context [Internet]. Front. Public Heal. 2021. Available from: https://www.frontiersin.org/article/10.3389/fpubh.2021.632043.
   Web of Science ®Google Scholar
• Rusnock AA. Historical context and the roots of Jenner’s discovery. Hum Vaccin Immunother [Internet]. 2016 March 22;12(8):2025–2028. Available from: https://pubmed.ncbi.nlm.nih.gov/27003336
   PubMed Web of Science ®Google Scholar
• Amanat F, Krammer F. SARS-CoV-2 vaccines: status Report. Immunity [Internet]. 2020;52(4):583–589. Available from: https://www.sciencedirect.com/science/article/pii/S1074761320301205
   PubMed Web of Science ®Google Scholar
• Arruda E, Cintra OAL, Hayden FG. Respiratory Tract Viral Infections. Guerrant RL, Walker DH, Weller PF, editors. Trop Infect Dis [Internet]. 2009 May 15;637–659. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7152450/
   Google Scholar
• Yang L, Xue X, Zeng T, et al. Novel biallelic TRNT1 mutations lead to atypical SIFD and multiple immune defects. Genes Dis [Internet]. 2020;7(1):128–137. Available from: https://www.sciencedirect.com/science/article/pii/S2352304220300131
   PubMed Web of Science ®Google Scholar
• Chen J-M. Should the world collaborate imminently to develop neglected live-attenuated vaccines for COVID-19?J Med Virol [Internet]. 2022;94(1):82–87
   PubMed Web of Science ®Google Scholar
• Kyriakidis NC, López-Cortés A, González EV, et al. SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. NPJ Vaccines [Internet]. 2021;6(1):28.
   PubMed Web of Science ®Google Scholar
• Minor PD. Live attenuated vaccines: historical successes and current challenges. Virology. 2015;479–480:379–392.
   PubMed Web of Science ®Google Scholar
• Kaur SP, Gupta V. COVID-19 Vaccine: a comprehensive status report. Virus Res Internet]. 2020 August 13;288:198114. Available from: https://pubmed.ncbi.nlm.nih.gov/32800805
   PubMed Web of Science ®Google Scholar
• Dong Y, Dai T, Wei Y, et al. A systematic review of SARS-CoV-2 vaccine candidates. Signal Transduct Target Ther [Internet]. 2020;5(1):237
   PubMed Web of Science ®Google Scholar
• Trimpert J, Adler JM, Eschke K, et al. Live attenuated virus vaccine protects against SARS-CoV-2 variants of concern B.1.1.7 (Alpha) and B.1.351 (Beta). Sci Adv. 2021;7(49):eabk0172.
   PubMed Web of Science ®Google Scholar
• Okamura S, Ebina H. Could live attenuated vaccines better control COVID-19? Vaccine. 2021;39(39):5719–5726.
   PubMed Web of Science ®Google Scholar
• Sanders B, Koldijk M, Schuitemaker H. Inactivated viral vaccines. vaccine anal. strateg. princ. Control. 2014;45–80.
   Google Scholar
• Lee N-H, Lee J-A, Park S-Y, et al. A review of vaccine development and research for industry animals in Korea. Clin Exp Vaccine Res. Internet]. 2012 July 31;1(1):18–34. Available from: https://pubmed.ncbi.nlm.nih.gov/23596575
   PubMedGoogle Scholar
• Jeyanathan M, Afkhami S, Smaill F, et al., Immunological considerations for COVID-19 vaccine strategies. Nat Rev Immunol. 2020;20(10): 615–632.
   PubMed Web of Science ®Google Scholar
• Sharma O, Sultan AA, Ding H, et al. A review of the progress and challenges of developing a vaccine for COVID-19. Front Immunol. 2020;11:1–17.
   PubMed Web of Science ®Google Scholar
• Ella R, Vadrevu KM, Jogdand H, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial. Lancet Infect Dis [Internet]. 2021;21(5):637–646.
   PubMed Web of Science ®Google Scholar
• Dolgin E. Omicron thwarts some of the world’s most-used COVID vaccines. Nature England. 2022;601(7893):311.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Patel AB, Vihol D, et al. Herbal remedies, nutraceuticals, and dietary supplements for COVID-19 management: an update. Clin Complement Med Pharmacol [Internet]. 2022;100021. Available from: https://www.sciencedirect.com/science/article/pii/S2772371222000031
   Google Scholar
• Chavda VP, Apostolopoulos V. Is booster dose strategy sufficient for omicron variant of SARS-CoV-2? Vaccines (Basel). 2022;10(3):367.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Apostolopoulos V. Omicron Variant (B.1.1.529) of SARS-CoV-2: threat for the elderly? Maturitas. 2022;158:78–81. Internet]
   PubMed Web of Science ®Google Scholar
• Chavda VP, Kapadia C, Soni S, et al. A global picture: therapeutic perspectives for COVID-19. Immunotherapy [Internet]. 2022;10.2217/imt;10.2217/imt20210168.20210168.
   Web of Science ®Google Scholar
• Basu D, Chavda VP, Mehta AA. Therapeutics for COVID-19 and post COVID-19 complications: an update. Curr Res Pharmacol Drug Discov. [Internet]. 2022;100086. https://www.sciencedirect.com/science/article/pii/S2590257122000062
   Google Scholar
• Chavda VP, Apostolopoulos V. Global impact of delta plus variant and vaccination. Expert Rev Vaccines. Internet]. 2022;null;nullnull. Available from;21(5):597–600.
   PubMed Web of Science ®Google Scholar
• Chua BY, Sekiya T, Jackson DC. Opinion: making inactivated and subunit-based vaccines work. Viral Immunol. 2018;31(2):150–158.
   PubMed Web of Science ®Google Scholar
• Tsoras AN, Champion JA. Protein and peptide biomaterials for engineered subunit vaccines and immunotherapeutic applications. Annu Rev Chem Biomol Eng. 2019;10(1):337–359.
   PubMedGoogle Scholar
• Degos F. Protein subunit vaccines: example of vaccination against hepatitis B virus. Rev Prat. 1995;45(12):1488–1491.
   PubMedGoogle Scholar
• Chlamydas S, Papavassiliou AG, Piperi C. Epigenetic mechanisms regulating COVID-19 infection. Epigenetics. 2021;16(3):263–270.
   PubMed Web of Science ®Google Scholar
• Mohsen MO, Zha L, Cabral-Miranda G, et al. Major findings and recent advances in virus-like particle (VLP)-based vaccines. Semin Immunol. 2017;34:123–132.
   PubMed Web of Science ®Google Scholar
• Medicago. Medicago and gsk start phase 3 trial of adjuvanted COVID-19 vaccine candidate [Internet]. March 16, 2021. 2021. cited 2021 Apr 10]. Available from: https://www.medicago.com/en/media-room/medicago-and-gsk-start-phase-3-trial-of-adjuvanted-covid-19-vaccine-candidate/.
   Google Scholar
• Ura T, Yamashita A, Mizuki N, et al. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates. Vaccine. 2021;39(2):197–201.
   PubMed Web of Science ®Google Scholar
• Morris SJ, Sebastian S, Spencer AJ, et al. Simian adenoviruses as vaccine vectors. Future Virol. 2016;11(9):649–659.
   PubMed Web of Science ®Google Scholar
• Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. 2021. Vol. 397. England: Lancet (London). p. 99–111.
   Google Scholar
• Sadoff J, Le Gars M, Shukarev G, et al. Interim results of a phase 1-2a trial of Ad26.COV2.S Covid-19 vaccine. N Engl J Med. 2021;384(19):1824–1835.
   PubMed Web of Science ®Google Scholar
• Machhi J, Shahjin F, Das S, et al. Nanocarrier vaccines for SARS-CoV-2. Adv Drug Deliv Rev. 2021;171:215–239.
   PubMed Web of Science ®Google Scholar
• Smith TRF, Patel A, Ramos S, et al. Immunogenicity of a DNA vaccine candidate for COVID-19. Nat Commun. 2020;11(1):2601.
   PubMed Web of Science ®Google Scholar
• de Queiroz NMGP, V MF, Chagas MA, et al. Vaccines for COVID-19: perspectives from nucleic acid vaccines to BCG as delivery vector system. Microbes Infect. 2020;22(10):515–524.
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Weissman D. Recent advances in mRNA vaccine technology. Curr Opin Immunol. 2020;65:14–20.
   PubMed Web of Science ®Google Scholar
• Shah D, Vivek Chavda HT. Nasal medication conveyance framework: an approach for brain delivery from essential to cutting edge. Res Rev J Med. 2016;6:14–27.
   Google Scholar
• Mudgal R, Nehul S, Tomar S. Prospects for mucosal vaccine: shutting the door on SARS-CoV-2. Hum Vaccin Immunother [Internet]. 2020;16(12):2921–2931
   PubMed Web of Science ®Google Scholar
• Chavda VP. Dendritic cell-based vaccine: the state-of-the-art vaccine platform for COVID-19 management. Expert Rev Vaccines 2022. 2022 (Ahead of print);1–9. http://doi.org/10.1080/14760584.2022.2110076
   Google Scholar
• Fu C, Zhou L, Q-S M, et al. Plasmacytoid dendritic cells and cancer immunotherapy. Cells. 2022;11(2):222.
   PubMed Web of Science ®Google Scholar
• Dave JB. Novel coronavirus pandemic- stark realities and new lessons for science & humanity. Pharma Times. 2021;52(4):9–14.
   Google Scholar
• Azuma K, Yanagi U, Kagi N, et al. Environmental factors involved in SARS-CoV-2 transmission: effect and role of indoor environmental quality in the strategy for COVID-19 infection control. Environ Health Prev Med. 2020;25(1):66.
   PubMed Web of Science ®Google Scholar
• Leung NHL. Transmissibility and transmission of respiratory viruses.Nat Rev Microbiol [Internet]. 2021;19(8):528–545
   PubMed Web of Science ®Google Scholar
• Ren S-Y, Wang W-B, Hao Y-G, et al. Stability and infectivity of coronaviruses in inanimate environments. World J Clin Cases [Internet]. 2020;8(8):1391–1399. Available from: https://pubmed.ncbi.nlm.nih.gov/32368532
   PubMed Web of Science ®Google Scholar
• Piana A, Colucci ME, Valeriani F, et al. Monitoring COVID-19 transmission risks by quantitative real-time pcr tracing of droplets in hospital and Living environments. mSphere. 2021;6(1):e01070–20.
   PubMed Web of Science ®Google Scholar
• Meyerowitz EA, Richterman A, Gandhi RT, et al. Transmission of SARS-CoV-2: a review of viral, host, and environmental factors. Ann Intern Med. 2021;174(1):69–79.
   PubMed Web of Science ®Google Scholar
• Duffy S, Bowles C, Perera CJ. Why are RNA virus mutation rates so damn high ? Exp Neurol. 2018;300:1–6.
   PubMedGoogle Scholar
• Frampton D, Rampling T, Cross A, et al. Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study. Lancet Infect Dis [Internet]. 2021;21(9):1246–1256.
   PubMed Web of Science ®Google Scholar
• Khateeb J, Li Y, Zhang H. Emerging SARS-CoV-2 variants of concern and potential intervention approaches.Crit Care [Internet]. 2021;25(1):244
   PubMed Web of Science ®Google Scholar
• Planas D, Veyer D, Baidaliuk A, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021;596(7871):276–280.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Ertas YN, Walhekar V, et al. Advanced computational methodologies used in the discovery of new natural anticancer compounds. Front Pharmacol. 2021;12:702611.
   PubMed Web of Science ®Google Scholar
• Guy RK, DiPaola RS, Romanelli F, et al. Rapid repurposing of drugs for COVID-19. Science. 2020;368(6493):829–830.
   PubMed Web of Science ®Google Scholar
• Farne H, Kumar K, Ritchie AI, et al. Repurposing existing drugs for the treatment of COVID-19. Ann Am Thorac Soc. 2020;17(10):1186–1194.
   PubMed Web of Science ®Google Scholar
• Joshi S, Parkar J, Ansari A, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis IJID Off Publ Int Soc Infect Dis. 2021;102:501–508.
   PubMed Web of Science ®Google Scholar
• Briggs N, V GM, Li F, et al. Early but not late convalescent plasma is associated with better survival in moderate-to-severe COVID-19. PLoS One [Internet]. 2021;16(7):e0254453
   PubMed Web of Science ®Google Scholar
• Takashita E, Kinoshita N, Yamayoshi S, et al. Efficacy of antibodies and antiviral drugs against Covid-19 omicron variant. N Engl J Med [Internet]. 2022;386(10):995–998
   PubMed Web of Science ®Google Scholar
• Sarma P, Prajapat M, Avti P, et al. Therapeutic options for the treatment of 2019-novel coronavirus: an evidence-based approach. Indian J Pharmacol. 2020;52(1):1–5.
   PubMed Web of Science ®Google Scholar
• Vaccine hesitancy: understanding and addressing vaccine hesitancy during COVID-19. American pharmacists association. Updated November 30, 2020. cited 2021 Jan 18. Available from: https://www.pharmacist.com/sites/default/files/audience/APhACOVID-19VaccineHesitancy
   Google Scholar
• Dubé E, MacDonald NE. COVID-19 vaccine hesitancy.Nat Rev Nephrol [Internet]. 2022;18(7):409–410
   PubMed Web of Science ®Google Scholar
• Pardi N, Hogan MJ, Porter FW, et al. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.
   PubMed Web of Science ®Google Scholar
• Regev-Yochay G, Gonen T, Gilboa M, et al. Efficacy of a fourth dose of covid-19 mRNA vaccine against omicron. N Engl J Med [Internet]. 2022;386(14):1377–1380.
   PubMed Web of Science ®Google Scholar
• Rosa SS, Prazeres DMF, Azevedo AM, et al. mRNA vaccines manufacturing: challenges and bottlenecks. Vaccine. 2021;39(16):2190–2200.
   PubMed Web of Science ®Google Scholar
• Crommelin DJA, Volkin DB, Hoogendoorn KH, et al. The science is there: key considerations for stabilizing viral vector-based Covid-19 vaccines. J Pharm Sci. 2021;110(2):627–634.
   PubMed Web of Science ®Google Scholar
• Kesselheim AS, Darrow JJ, Kulldorff M, et al. An overview of vaccine development, approval, and regulation, with implications for COVID-19. Health Aff (Millwood). 2021;40(1):25–32.
   PubMed Web of Science ®Google Scholar
• Vasileiou E, Simpson CR, Shi T, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet [Internet]. 2021;397(10285):1646–1657.
   PubMed Web of Science ®Google Scholar
• Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615.
   PubMed Web of Science ®Google Scholar
• Turner PJ, Ansotegui IJ, Campbell DE, et al. COVID-19 vaccine-associated anaphylaxis: a statement of the world allergy organization anaphylaxis committee. World Allergy Organ J [Internet]. 2021;14(2):100517. https://www.sciencedirect.com/science/article/pii/S1939455121000119
   PubMed Web of Science ®Google Scholar
• Shimabukuro, Tom Allergic reactions including anaphylaxis after receipt of the first dose of Pfizer-BioNTech COVID-19 vaccine - United States. MMWR Morb Mortal Wkly Rep. 2020 Dec 14-23; 70(2)46–51
   Web of Science ®Google Scholar
• Wise J. Covid-19: rare immune response may cause clots after AstraZeneca vaccine, say researchers. BMJ. 2021;373(n954 1).
   Google Scholar
• Magnus MC, Gjessing HK, Eide HN, et al. Covid-19 vaccination during pregnancy and first-trimester miscarriage. N Engl J Med [Internet]. 2021;385(21):2008–2010
   PubMed Web of Science ®Google Scholar
• Schoenmaker L, Witzigmann D, Kulkarni JA, et al. mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability. Int J Pharm. 2021;601:120586.
   PubMed Web of Science ®Google Scholar
• Kojima N, Klausner JD. Protective immunity after recovery from SARS-CoV-2 infection. Lancet Infect Dis. 2022;22(1):12–14.
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Burke PC, Nowacki AS, et al. Necessity of coronavirus disease 2019 (COVID-19) vaccination in persons who have already had COVID-19. Clin Infect Dis. 2022;74(1):1–25.
   PubMedGoogle Scholar
• Pilz S, Chakeri A, Ioannidis JP, et al. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021;51(4):e13520.
   PubMed Web of Science ®Google Scholar
• CDC. Frequently asked questions about COVID-19 vaccination. CDC. January 15, 2021. USFDA.
   Google Scholar
• Rodrigues CMC, Plotkin SA. Impact of vaccines; health, economic and social perspectives. Front. Microbiol [Internet]. 2020. https://www.frontiersin.org/article/10.3389/fmicb.2020.01526.
   Web of Science ®Google Scholar
• Hervé C, Laupèze B, Del Giudice G, et al. The how’s and what’s of vaccine reactogenicity. npj Vaccines. NPJ Vaccines [Internet]. 2019;4:39
   PubMed Web of Science ®Google Scholar
• Gonzalez-Dias P, Lee EK, Sorgi S, et al. Methods for predicting vaccine immunogenicity and reactogenicity. Hum Vaccin Immunother. [Internet]. 2019 December 23;16(2):269–276. Available from: https://pubmed.ncbi.nlm.nih.gov/31869262
   PubMed Web of Science ®Google Scholar
• Andrews N, Tessier E, Stowe J, et al. Duration of protection against mild and severe disease by Covid-19 vaccines. N Engl J Med. 2022;386(4):340–350.
   PubMed Web of Science ®Google Scholar
• Weisblum Y, Schmidt F, Zhang F, et al. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants. Elife. 2020;9.
   PubMed Web of Science ®Google Scholar
• Cao Y, Yisimayi A, Jian F, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection. Nature. 2022;608(7923):593–602.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Hanuma Kumar Ghali EN, Yallapu MM, et al. Therapeutics to tackle Omicron outbreak. Immunotherapy [Internet]. 2022;14(11):833–838.
   PubMed Web of Science ®Google Scholar
• Vivek PC. Omicron variant (B.1.1.529) of SARS-CoV-2: threat for the elderly? 2020;• Describe the omicron variant of SARS-CoV-2.
   Google Scholar
• Krause PR, Fleming TR, Peto R, et al. Considerations in boosting COVID-19 vaccine immune responses. Lancet [Internet. 2021;398(10308):1377–1380
   PubMed Web of Science ®Google Scholar
• UK Government. COVID-19 vaccine surveillance report - week 9 [Internet]. 2022 cited 2022 May 4]. Available from: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1058464/Vaccine-surveillance-report-week-9.pdf.
   Google Scholar
• Munro APS, Feng S, Janani L, et al. Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial 2022;22(8):1131–1141.
   Google Scholar
• Chen F, Zhu S, Dai Z, et al. Effects of COVID-19 and mRNA vaccines on human fertility. Hum Reprod. 2021;37(1):5–13.
   PubMed Web of Science ®Google Scholar
• Wu K, Werner AP, Moliva JI, et al. mRNA-1273 vaccine induces neutralizing antibodies against spike mutants from global SARS-CoV-2 variants. bioRxiv Prepr Serv Biol. 2021. doi: 10.1101/2021.01.25.427948.
   Google Scholar
• Xie X, Liu Y, Liu J, et al. Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K and N501Y variants by BNT162b2 vaccine-elicited sera. Nat Med. 2021;27(4):620–621.
   PubMed Web of Science ®Google Scholar
• Gonzalez DC, Nassau DE, Khodamoradi K, et al. Sperm parameters before and after COVID-19 mRNA vaccination. JAMA [Internet]. 2021;326(3):273–274
   PubMed Web of Science ®Google Scholar
• Wesselink AK, Hatch EE, Rothman KJ, et al. A prospective cohort study of COVID-19 vaccination, SARS-CoV-2 infection, and fertility. Am J Epidemiol [Internet]. 2022;191(8):1383–1395.
   PubMed Web of Science ®Google Scholar
• Rajak P, Roy S, Dutta M, et al. Understanding the cross-talk between mediators of infertility and COVID-19. Reprod Biol. 2021;21(4):100559.
   PubMed Web of Science ®Google Scholar
• Roychoudhury S, Das A, Jha NK, et al. Viral pathogenesis of SARS-CoV-2 infection and male reproductive health. 2021;2:1–11.
   Google Scholar
• Ikemura N, Hoshino A, Higuchi Y, et al. SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies. medRxiv [Internet]. 2021 December 13;21267761. Available from: http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267761.abstract.
   Google Scholar
• Mahase E. Covid-19: what do we know about omicron sublineages? BMJ [Internet]. 2022;376:o358. Available from: http://www.bmj.com/content/376/bmj.o358.abstract
   PubMedGoogle Scholar
• Chandler RE. COmmEnT optimizing safety surveillance for COVID-19 vaccines. Nat Rev Immunol. 2020;20(8):451–452.
   PubMed Web of Science ®Google Scholar
• Tau N, Yahav D, Shepshelovich D. Vaccine safety - is the SARS-CoV-2 vaccine any different? Hum Vaccin Immunother. 2021;17(5):1322–1325.
   PubMed Web of Science ®Google Scholar
• Krause PR, Gruber MF. Emergency use authorization of covid vaccines - safety and efficacy follow-up considerations. N Engl J Med. 2020;383(19):e107.
   PubMed Web of Science ®Google Scholar
• Walsh EE, Frenck RWJ, Falsey AR, et al. Safety and Immunogenicity of two RNA-based covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439–2450.
   PubMed Web of Science ®Google Scholar
• Xing K, X-y T, Liu M, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(3):221–228.
   PubMedGoogle Scholar
• Kaur RJ, Dutta S, Bhardwaj P, et al. Adverse events reported from COVID-19 vaccine trials: a systematic review. Indian J Clin Biochem. 2021;36(4):1–13.
   PubMed Web of Science ®Google Scholar
• Ali N. Relationship between COVID-19 infection and liver injury: a review of recent data. Front Med. 2020;7:458.
   Web of Science ®Google Scholar
• Saeed BQ, Al-Shahrabi R, Alhaj SS, et al. Side effects and perceptions following Sinopharm COVID-19 vaccination. Int J Infect Dis [Internet]. 2021;111:219–226. Available from: https://www.sciencedirect.com/science/article/pii/S1201971221006469
   PubMed Web of Science ®Google Scholar
• Formica N, Mallory R, Albert G, et al. Different dose regimens of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373) in younger and older adults: a phase 2 randomized placebo-controlled trial. PLoS Med. 2021;18(10):e1003769.
   PubMed Web of Science ®Google Scholar
• Dunkle LM, Kotloff KL, Gay CL, et al. Efficacy and safety of NVX-CoV2373 in adults in the United States and Mexico. N Engl J Med. 2022;386(6):531–543.
   PubMed Web of Science ®Google Scholar
• Chadwick DR, Clark R, Cosgrove C, et al. Safety and efficacy of NVX-CoV2373 Covid-19 vaccine. The New England Journal of Medicine. 2021;385(13):1172–1183.
   PubMed Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2020;384(5):403–416.
   PubMed Web of Science ®Google Scholar
• Remmel A. COVID vaccines and safety: what the research says. Nat England. 2021;590(7847):538–540.
   Google Scholar
• Gargano JW, Wallace M, Hadler SC, et al. Use of mRNA COVID-19 vaccine after reports of myocarditis among vaccine recipients: update from the advisory committee on immunization practices — United States, june 2021. MMWR Morb Mortal Wkly Rep. 2021;70(27):977–982.
   PubMed Web of Science ®Google Scholar
• Sadoff J, Gray G, Vandebosch A, et al. Final analysis of efficacy and safety of single-dose Ad26.COV2.S. N Engl J Med. 2022;386(9):847–860.
   PubMed Web of Science ®Google Scholar
• Ella R, Reddy S, Blackwelder W, et al. Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. 2021;398(10317):2173–2184.
   PubMed Web of Science ®Google Scholar
• Choi G-J, Baek SH, Kim J, et al. Fatal systemic capillary leak syndrome after SARS-CoV-2Vaccination in patient with multiple myeloma. Emerg Infect Dis. [Internet]. 2021 August 30;27(11):2973–2975. Available from: https://pubmed.ncbi.nlm.nih.gov/3445972510.3201/eid2711.211723
   PubMed Web of Science ®Google Scholar
• Fasano G, Bennardo L, Ruffolo S, et al. Erythema migrans-like COVID vaccine arm: a literature review. J Clin Med. 2022;11(3):11.
   Web of Science ®Google Scholar
• Petruzzi M, Galleggiante S, Messina S, et al. Oral erythema multiforme after Pfizer-BioNTech COVID-19 vaccination: a report of four cases. BMC Oral Health. 2022;22(1):90.
   PubMed Web of Science ®Google Scholar
• Petersen MB, Bor A, Jørgensen F, et al. Transparent communication about negative features of COVID-19 vaccines decreases acceptance but increases trust. Proc Natl Acad Sci [Internet]. 2021;11829):e2024597118. Available from: http://www.pnas.org/content/118/29/e2024597118.abstract
   PubMed Web of Science ®Google Scholar
• Black SB, Law B, Chen RT, et al. The critical role of background rates of possible adverse events in the assessment of COVID-19 vaccine safety. Vaccine. 2021;39(19):2712–2718.
   PubMed Web of Science ®Google Scholar
• Chavda VP, Bezbaruah R, Athalye M, et al. Replicating viral vector-based vaccines for COVID-19: potential avenue in vaccination arena. Viruses. 2022;14(4):759.
   PubMed Web of Science ®Google Scholar
• Lee JX, Chieng WK, Lau SCD, et al. COVID-19 and hemoglobinopathies: a systematic review of clinical presentations, investigations, and outcomes. Front Med [Internet]. 2021;8:757510. https://pubmed.ncbi.nlm.nih.gov/34722593
   Web of Science ®Google Scholar
• Karimi M, Zarei T, Haghpanah S, et al. Efficacy and safety of sinopharm vaccine for SARS-COV-2 and breakthrough infections in Iranian patients with hemoglobinopathies: a preliminary report. Mediterr J Hematol Infect Dis. 2022;14(1):e2022026–e2022026.
   PubMedGoogle Scholar
• Rossman H, Shilo S, Meir T, et al. COVID-19 dynamics after a national immunization program in Israel. Nat Med [Internet]. 2021;27(6):1055–1061
   PubMed Web of Science ®Google Scholar
• Doherty M, Buchy P, Standaert B, et al. Vaccine impact: benefits for human health. Vaccine. 2016;34(52):6707–6714.
   PubMed Web of Science ®Google Scholar
• Bartsch SM, O’Shea KJ, Ferguson MC, et al. Vaccine efficacy needed for a COVID-19 coronavirus vaccine to prevent or stop an epidemic as the sole intervention. Am J Prev Med [Internet]. 2020;59(4):493–503
   PubMed Web of Science ®Google Scholar
• Kashte S, Gulbake A, El-Amin Iii SF, et al. COVID-19 vaccines: rapid development, implications, challenges and future prospects. Hum Cell. 2021;34(3):1–23.
   PubMed Web of Science ®Google Scholar
• Krammer F. SARS-CoV-2 vaccines in development.Nature [Internet]. 2020;586(7830):516–527
   PubMed Web of Science ®Google Scholar
• Sridhar S, Luedtke A, Langevin E, et al. Effect of Dengue serostatus on dengue vaccine safety and efficacy. N Engl J Med. 2018;379(4):327–340.
   PubMed Web of Science ®Google Scholar
• Biswas A. A statistician explains: what does ‘90% efficacy’ for a Covid-19 vaccine mean? Scroll. 2021. Available from: https://scroll.in/article/979627/a-statistician-ex
   Google Scholar
• WHO. WHO target product profiles for COVID-19 vaccines version 3–29 April 2020. WHO World Heal Organ. 2020, 1–7. Available from: https://www.who.int/publications/m/item/who-target-product-profilesfor-covid-19-vaccines
   Google Scholar
• Collie S, Champion J, Moultrie H, et al. Effectiveness of BNT162b2 vaccine against omicron variant in South Africa. N Engl J Med. 2022;386(5):494–496.
   PubMed Web of Science ®Google Scholar
• Cele S, Jackson L, Khoury DS, et al. Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization. Nature. 2022;602(7898):654–656.
   PubMed Web of Science ®Google Scholar
• Syed AM, Ciling A, Khalid MM, et al. Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-CoV-2 virus-like particles. PNAS Microbiology. 2022;119(31): e2200592119. https://doi.org/10.1073/pnas.2200592119
   PubMedGoogle Scholar
• Cao Y, Wang J, Jian F, et al. Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies. Nature. 2022;602(7898):657–663.
   PubMed Web of Science ®Google Scholar
• Araf Y, Akter F, Tang Y-D, et al. Omicron variant of SARS-CoV-2: genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol. 2022;94(5):1825–1832.
   PubMed Web of Science ®Google Scholar
• Sievers BL, Chakraborty S, Xue Y, et al. Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses. Sci Transl Med. 2022;14(634):eabn7842.
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: implications for control of the COVID-19 pandemic. Cell. 2022;185(3):447–456.e11.
   PubMed Web of Science ®Google Scholar
• Malik JA, Ahmed S, Mir A, et al. The SARS-CoV-2 mutations versus vaccine effectiveness: new opportunities to new challenges. J Infect Public Health [Internet]. 2022;15(2): 228–240. Available from: https://www.sciencedirect.com/science/article/pii/S1876034122000028
   PubMed Web of Science ®Google Scholar
• Tseng HF, Ackerson BK, Luo Y, et al. Effectiveness of mRNA-1273 against SARS-CoV-2 omicron and delta variants. Nat Med. 2022;28:1063–1071.
   PubMed Web of Science ®Google Scholar
• Li XO. Call for updated vaccines. J Med Virol. 2022;94(4):1261–1263.
   PubMed Web of Science ®Google Scholar
• Cameroni E, Bowen JE, Rosen LE, et al. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift. Nature. 2022;602(7898):664–670.
   PubMed Web of Science ®Google Scholar
• Duan X, Shi R, Liu P, et al. A non-ACE2-blocking neutralizing antibody against Omicron-included SARS-CoV-2 variants. Signal Transduct Target Ther. 2022;7(1):23.
   PubMed Web of Science ®Google Scholar
• Thanh Le T, Andreadakis Z, Kumar A, et al. The COVID-19 vaccine development landscape. Nat Drug Disc. 2020;19(5):305–306. Apr 9 posting date.
   PubMed Web of Science ®Google Scholar
• Arabi YM, Asseri A, Webb S, et al. Clinical trials for coronavirus disease 2019: what is being evaluated and what is not. Ann Thorac Med. 2020;15(2):49–51.
   PubMed Web of Science ®Google Scholar
• Calina D, Docea AO, Petrakis D, et al. Towards effective COVID‑19 vaccines: updates, perspectives and challenges (Review). Int J Mol Med [Internet]. 2020 May 06;46:3–16. Available from: https://pubmed.ncbi.nlm.nih.gov/32377694
   PubMed Web of Science ®Google Scholar
• Flores LE, Frontera WR, Andrasik MP, et al. Assessment of the inclusion of racial/ethnic minority, female, and older individuals in vaccine clinical trials. JAMA Network Open [Internet]. 2021;4(2):e2037640–e2037640.
   PubMed Web of Science ®Google Scholar
• Riley LE. mRNA Covid-19 vaccines in pregnant women. N Engl J Med.2021;384(24):2342–2343;[Internet]
   PubMed Web of Science ®Google Scholar
• Lavazza A, Farina M. The role of experts in the Covid-19 pandemic and the limits of their epistemic authority in democracy [Internet]. Front. Public Heal. 2020. 356. https://www.frontiersin.org/article/10.3389/fpubh.2020.00356
   PubMed Web of Science ®Google Scholar
• Giordano G, Blanchini F, Bruno R, et al. Modelling the COVID-19 epidemic and implementation of population-wide interventions in Italy. Nat Med [Internet]. 2020;26(6):855–860
   PubMed Web of Science ®Google Scholar
• Wang CJ, Ng CY, Brook RH. Response to COVID-19 in Taiwan: big data analytics, new technology, and proactive testing. JAMA [Internet]. 2020;323(14):1341–1342
   PubMed Web of Science ®Google Scholar
• Sample I. Research finds huge impact of interventions on spread of Covid-19. Guard, 11. [Internet]. 2020 [cited 2021 Nov 13]. Mar 2020. Available from: https://www.theguardian.com/world/2020/mar/11/research-finds-huge-impact-of-interventions-on-spread-of-covid-19.
   Google Scholar
• ICH Q9 quality risk management. Step. 4. (2005).
   Google Scholar
• Milá L, Valdés R, Tamayo A, et al. Application of a risk analysis method to different technologies for producing a monoclonal antibody employed in hepatitis B vaccine manufacturing. Biologicals. 2012;40(2):118–128.
   PubMed Web of Science ®Google Scholar
• Jindani R, Sheth S, Paul S, et al. Platform-specific risk assessment of SARS-CoV-2 vaccines using FMEA. [Internet] Feb 2 2021 [cited 2021 Apr 10]. Available from: https://www.biopharminternational.com/view/platform-specific-risk-assessment-of-sars-cov-2-vaccines-using-fmea.
   Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:614.
   Web of Science ®Google Scholar
• Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial. Lancet [Internet]. 2021;398(10318):P2258–2276.
   PubMed Web of Science ®Google Scholar